Point72 discloses 6.8% Century Therapeutics (IPSC) stake in 13G/A

Rhea-AI Filing Summary

Century Therapeutics, Inc. (IPSC) received an updated ownership filing showing that Point72 entities report beneficial ownership of 5,961,563 common shares, representing 6.8% of the company. The stake is held through Point72 Associates, LLC, with Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen reporting shared voting and investment power.

The information is stated as of the close of business on January 2, 2026 and is filed as Amendment No. 1 to correct beneficial ownership previously disclosed. The reporting persons certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Century Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

15673T100

(CUSIP Number)

12/23/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 15673T100

1

Names of Reporting Persons

Point72 Asset Management, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,961,563.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,961,563.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,961,563.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: This Amendment No. 1 to the Schedule 13G amends and restates the original Schedule 13G filed on January 5, 2026 to correct the beneficial ownership disclosed therein.

SCHEDULE 13G

CUSIP No. 15673T100

1

Names of Reporting Persons

Point72 Capital Advisors, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,961,563.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,961,563.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,961,563.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: This Amendment No. 1 to the Schedule 13G amends and restates the original Schedule 13G filed on January 5, 2026 to correct the beneficial ownership disclosed therein.

SCHEDULE 13G

CUSIP No. 15673T100

1

Names of Reporting Persons

Steven A. Cohen

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 5,961,563.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 5,961,563.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

5,961,563.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: This Amendment No. 1 to the Schedule 13G amends and restates the original Schedule 13G filed on January 5, 2026 to correct the beneficial ownership disclosed therein.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Century Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 25 N 38th Street, 11th Floor, Philadelphia, PA 19104
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.0001 per share ("Shares"), of Century Therapeutics, Inc. held by Point72 Associates, LLC, an investment fund it manages ("Point72 Associates"); (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the Shares held by Point72 Associates; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc. Each of Cubist Systematic Strategies, LLC, Point72 Asia (Singapore) Pte. Ltd., and Point72 (DIFC) Limited are relying advisers on the Form ADV of Point72 Asset Management and each acts as a sub-advisor with respect to a portion of the Shares reported herein.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)	Citizenship: Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 15673T100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on January 2, 2026. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein.
(b)	Percent of class: 6.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on January 2, 2026.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on January 2, 2026.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on January 2, 2026.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on January 2, 2026.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a). Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Point72 Asset Management, L.P.

Signature:	/s/ Jason M. Colombo
Name/Title:	Jason M. Colombo, Authorized Person
Date:	02/17/2026

Point72 Capital Advisors, Inc.

Signature:	/s/ Jason M. Colombo
Name/Title:	Jason M. Colombo, Authorized Person
Date:	02/17/2026

Steven A. Cohen

Signature:	/s/ Jason M. Colombo
Name/Title:	Jason M. Colombo, Authorized Person
Date:	02/17/2026

FAQ

What ownership stake does Point72 report in Century Therapeutics (IPSC)?

Point72-related entities report beneficial ownership of 5,961,563 Century Therapeutics common shares, equal to 6.8% of the outstanding class. The stake is held through Point72 Associates, LLC, with shared voting and dispositive power reported by affiliated Point72 entities and Steven A. Cohen.

Which Point72 entities are reporting beneficial ownership in IPSC?

The filing lists Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as reporting persons. The shares are held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management, with the other reporting persons controlling that adviser structure.

How many Century Therapeutics (IPSC) shares are beneficially owned according to this amendment?

The amendment states beneficial ownership of 5,961,563 Century Therapeutics common shares. All reporting persons list zero sole voting or dispositive power and the same 5,961,563 shares under shared voting and shared dispositive power, representing a 6.8% position in the issuer.

Is the Point72 position in Century Therapeutics (IPSC) passive or for control purposes?

The reporting persons certify the securities were not acquired and are not held to change or influence control of Century Therapeutics. They state the holdings are not in connection with any transaction having that purpose, other than activities solely related to a nomination under specific proxy rules.

What is the purpose of Amendment No. 1 in this IPSC Schedule 13G/A?

Amendment No. 1 amends and restates the original ownership report filed on January 5, 2026, to correct the beneficial ownership previously disclosed. All three reporting persons include this explanation in their cover-page comments, indicating the change is administrative rather than a new transaction.

Who ultimately controls the Point72 entities reporting IPSC ownership?

The filing explains that Point72 Capital Advisors, Inc. is the general partner of Point72 Asset Management, and Steven A. Cohen controls both entities. Through this structure, Mr. Cohen is reported as indirectly sharing voting and dispositive power over the Century Therapeutics shares held by Point72 Associates.